Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 14 results.
User Information
Export Records
  1. 1.   Prediction of differential Gag versus Env responses to a mosaic HIV-1 vaccine regimen by HLA class I alleles
  2. Nelson,George; van Duijn, Janine; Yuki,Yuko; Pau, Maria G; Tomaka, Frank; Lavreys, Ludo; DeRosa, Steven C; McElrath, M Juliana; Kirk, Gregory D; Michael, Nelson L; Haas, David W; Deeks, Steven G; Wolinsky, Steven; Walker, Bruce; Barouch, Dan H; Stieh, Daniel; Carrington, Mary
  3. Journal of Virology. 2024, Jul 24; e0028124.
  1. 2.   HIV-1 neutralizing antibodies elicited in humans by a prefusion-stabilized envelope trimer form a reproducible class targeting fusion peptide
  2. Wang, Shuishu; Matassoli, Flavio; Zhang, Baoshan; Liu, Tracy; Shen, Chen-Hsiang; Bylund, Tatsiana; Johnston, Timothy; Henry, Amy R; Teng, I-Ting; Tripathi, Prabhanshu; Becker, Jordan E; Changela, Anita; Chaudhary, Ridhi; Cheng, Cheng; Gaudinski, Martin; Gorman, Jason; Harris, Darcy R; Lee, Myungjin; Morano, Nicholas C; Novik, Laura; O'Dell, Sijy; Olia, Adam S; Parchment, Danealle K; Rawi, Reda; Roberts-Torres, Jesmine; Stephens,Tyler; Tsybovsky,Yaroslav; Wang, Danyi; Van Wazer, David J; Zhou, Tongqing; Doria-Rose, Nicole A; Koup, Richard A; Shapiro, Lawrence; Douek, Daniel C; McDermott, Adrian B; Kwong, Peter D
  3. Cell Reports. 2023, Jul 10; 42(7): 112755.
  1. 3.   Immune Monitoring Reveals Fusion Peptide Priming to Imprint Cross-Clade HIV-Neutralizing Responses with a Characteristic Early B Cell Signature
  2. Cheng, Cheng; Duan, Hongying; Xu, Kai; Chuang, Gwo-Yu; Corrigan, Angela R; Geng, Hui; O'Dell, Sijy; Ou, Li; Chambers, Michael; Changela, Anita; Chen, Xuejun; Foulds, Kathryn E; Sarfo, Edward K; Jafari, Alexander J; Hill, Kurt R; Kong, Rui; Liu, Kevin; Todd, John P; Tsybovsky,Yaroslav; Verardi, Raffaello; Wang, Shuishu; Wang, Yiran; Wu, Winston; Zhou, Tongqing; Arnold, Frank J; Doria-Rose, Nicole A; Koup, Richard A; McDermott, Adrian B; Scorpio, Diana G; Worobey, Michael; Shapiro, Lawrence; Mascola, John R; Kwong, Peter D
  3. Cell reports. 2020, Aug 04; 32(5): 107981.
  1. 4.   A Neutralizing Antibody Recognizing Primarily N-Linked Glycan Targets the Silent Face of the HIV Envelope
  2. Zhou, Tongqing; Zheng, Anqi; Baxa, Ulrich; Chuang, Gwo-Yu; Georgiev, Ivelin S; Kong, Rui; O'Dell, Sijy; Shahzad-Ul-Hussan, Syed; Shen, Chen-Hsiang; Tsybovsky, Yaroslav; Bailer, Robert T; Gift, Syna K; Louder, Mark K; McKee, Krisha; Rawi, Reda; Stevenson, Catherine H; Stewart-Jones, Guillaume B E; Taft, Justin D; Waltari, Eric; Yang, Yongping; Zhang, Baoshan; Shivatare, Sachin S; Shivatare, Vidya S; Lee, Chang-Chun D; Wu, Chung-Yi; Mullikin, James C; Bewley, Carole A; Burton, Dennis R; Polonis, Victoria R; Shapiro, Lawrence; Wong, Chi-Huey; Mascola, John R; Kwong, Peter D; Wu, Xueling
  3. Immunity. 2018, Mar 20; 48(3): 500-513.e6.
  1. 5.   Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody
  2. Burton, D. R.; Hessell, A. J.; Keele, B. F.; Klasse, P. J.; Ketas, T. A.; Moldt, B.; Dunlop, D. C.; Poignard, P.; Doyle, L. A.; Cavacini, L.; Veazey, R. S.; Moore, J. P.
  3. Proceedings of the National Academy of Sciences of the United States of America. 2011, Jul; 108(27): 11181-11186.
  1. 6.   Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers
  2. Butterfield, L. H.; Palucka, A. K.; Britten, C. M.; Dhodapkar, M. V.; Hakansson, L.; Janetzki, S.; Kawakami, Y.; Kleen, T. O.; Lee, P. P.; Maccalli, C.; Maecker, H. T.; Maino, V. C.; Maio, M.; Malyguine, A.; Masucci, G.; Pawelec, G.; Potter, D. M.; Rivoltini, L.; Salazar, L. G.; Schendel, D. J.; Slingluff, C. L.; Song, W. R.; Stroncek, D. F.; Tahara, H.; Thurin, M.; Trinchieri, G.; van Der Burg, S. H.; Whiteside, T. L.; Wigginton, J. M.; Marincola, F.; Khleif, S.; Fox, B. A.; Disis, M. L.
  3. Clinical Cancer Research. 2011, May; 17(10): 3064-3076.
  1. 7.   Protective HLA Class I Alleles That Restrict Acute-Phase CD8(+) T-Cell Responses Are Associated with Viral Escape Mutations Located in Highly Conserved Regions of Human Immunodeficiency Virus Type 1
  2. Wang, Y.; Li, B.; Carlson, J. M.; Streeck, H.; Gladden, A. D.; Goodman, R.; Schneidewind, A.; Power, K. A.; Toth, I.; Frahm, N.; Alter, G.; Brander, C.; Carrington, M.; Walker, B. D.; Altfeld, M.; Heckerman, D.; Allen, T. M.
  3. Journal of Virology. 2009 83(4): 1845-1855.
  1. 8.   IgM, not IgG, a key for HIV vaccine
  2. Yang, Q. E.
  3. Vaccine. 2009 27(9): 1287-1288.
  1. 9.   Optimization of the doxycycline-dependent simian immunodeficiency virus through in vitro evolution
  2. Das, A. T.; Klaver, B.; Centlivre, M.; Harwig, A.; Ooms, M.; Page, M.; Almond, N.; Yuan, F.; Piatak, M.; Lifson, J. D.; Berkhout, B.
  3. Retrovirology. 2008 5 AR 44
  1. 10.   Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid
  2. Boyer, J. D.; Robinson, T. M.; Kutzler, M. A.; Vansant, G.; Hokey, D. A.; Kumar, S.; Parkinson, R.; Wu, L.; Sidhu, M. K.; Pavlakis, G. N.; Felber, B. K.; Brown, C.; Silvera, P.; Lewis, M. G.; Monforte, J.; Waldmann, T. A.; Eldridge, J.; Weiner, D. B.
  3. Proceedings of the National Academy of Sciences of the United States of America. 2007, Nov; 104(47): 18648-18653.
  1. 11.   Effect of CD8(+) lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239 Delta 3-vaccinated rhesus macaques
  2. Schmitz, J. E.; Johnson, R. P.; McClure, H. M.; Manson, K. H.; Wy, M. S.; Kuroda, M. J.; Lifton, M. A.; Khunkhun, R. S.; McEvers, K. J.; Gillis, J.; Piatak, M.; Lifson, J. D.; Grosschupff, G.; Racz, P.; Tenner-Racz, K.; Rieber, E. P.; Kuus-Reichel, K.; Gelman, R. S.; Letvin, N. L.; Montefiori, D. C.; Ruprecht, R. M.; Desrosiers, R. C.; Reimann, K. A.
  3. Journal of Virology. 2005, JUL; 79(13): 8131-8141.
  1. 12.   Reversion of CTL escape-variant immunodeficiency viruses in vivo
  2. Friedrich, T. C.; Dodds, E. J.; Yant, L. J.; Vojnov, L.; Rudersdorf, R.; Cullen, C.; Evans, D. T.; Desrosiers, R. C.; Mothe, B. R.; Sidney, J.; Sette, A.; Kunstman, K.; Wolinsky, S.; Piatak, M.; Lifson, J.; Hughes, A. L.; Wilson, N.; O'Connor, D. H.; Watkins, D. I.
  3. Nature Medicine. 2004 10(3): 275-281.
  1. 13.   Development of a Cyanovirin-N-HIV-1 gp120 binding assay for high throughput screening of natural product extracts by time-resolved fluorescence
  2. McMahon, J. B.; Beutler, J. A.; O'Keefe, B. R.; Goodrum, C. B. B.; Myers, M. A.; Boyd, M. R.
  3. Journal of Biomolecular Screening. 2000 5(3): 169-176.
  1. 14.   Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations
  2. Robinson, H. L.; Montefiori, D. C.; Johnson, R. P.; Manson, K. H.; Kalish, M. L.; Lifson, J. D.; Rizvi, T. A.; Lu, S.; Hu, S. L.; Mazzara, G. P.; Panicali, D. L.; Herndon, J. G.; Glickman, R.; Candido, M. A.; Lydy, S. L.; Wyand, M. S.; McClure, H. M.
  3. Nature Medicine. 1999 5(5): 526-534.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel